Up next

Autoplay

Urinary Markers in Bladder Cancer

0 Views • 06/16/23
Share
Embed
administrator
administrator
Subscribers
0

Dr. Peter Black, MD, discusses the benefits and limitations of the currently FDA approved and commercially available urinary biomarkers for bladder cancer, including UroVysion FISH, ImmunoCyt, AssureMDx, and CxBladder. He defines the yet-to-be-developed “ideal” marker, which would reduce the need for other diagnostic tests, have a high sensitivity and specificity rate, and be cost-effective for patients. Also, he discusses when it is possible to use markers in place of cystoscopy.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay